Evidence map›Paper›PMID 18395894›Full record

ReviewWorld journal of gastroenterology2008

Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.

M-I Torres, A Rios

Registry-linked trialOpen access · hybridAbstract readEditorialReview
In one paragraph

Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03594708 (Impact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis Patients), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03594708 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Impact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis Patients

TypeinterventionalSponsorBaptist Memorial Health Care CorporationRan2018 to 2018Enrolled30ConditionsUlcerative ColitisArmsNutrition supplement, Placebo supplement
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Role of CD34 in inflammatory bowel disease.Frontiers in physiology · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. The Immunological Basis of Inflammatory Bowel Disease.Gastroenterology research and practice · 2016
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M-I Torres
A Rios
Universidad de Jaén · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Al though the aetiology of inflammatory bowel disease (IBD) remains unknown, the pathogenesis is gradually being unravelled, seeming to be the result of a combination of environmental, genetic, and immunological factors in which an uncontrolled immune response within the intestinal lumen leads to inflammation in genetically predisposed individuals. Multifactorial evidence suggests that a defect of innate immune response to microbial agents is involved in IBD. This editorial outlines the immunopathogenesis of IBD and their current and future therapy. We present IBD as a result of dysregulated mucosal response in the intestinal wall facilitated by defects in epithelial barrier function and the mucosal immune system with excessive production of cytokines growth factors, adhesion molecules, and reactive oxygen metabolites, resulting in tissue injury. Established and evolving therapies are discussed in the second part of this editorial and at the end of this section we review new therapies to modulate the immune system in patients with IBD.

Indexed as

AnimalsApoptosisCytokinesDietDietary FiberFatty Acids, UnsaturatedFlavonoidsHumansImmune SystemInflammatory Bowel DiseasesModels, GeneticPlatelet Activating FactorProbioticsReactive Oxygen SpeciesCytokinesDietary FiberFatty Acids, UnsaturatedFlavonoidsPlatelet Activating FactorReactive Oxygen Species

Identifiers

PMID18395894
PMCPMC2701515
OpenAlexW2136494572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.